Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients

Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients

“…In the present study, we found no association between IL-18 polymorphisms and a higher risk of renal cancer. However, as in other studies [18,30], these polymorphisms were correlated with more advanced cancer stages. IL-18 promoter polymorphisms have been associated with other cancers, including prostate and colorectal carcinomas [31,32], although other authors found no association between IL-18 polymorphisms and cancer risk [33,34].…”

Association of HLA-G polymorphisms with nasopharyngeal carcinoma risk and clinical outcome

“…The association between age and NPC onset was demonstrated for several genes. Our previously described data suggest a significant correlation of NPC age-onset with HLA-class I, TAP-1, IL-18 promoter, IL-10, and IFN-␥ gene polymorphisms [8,[65][66][67]. A differential association with age onset was also demonstrated for a variety of biologic factors, like autoantibodies to tubulin or expression level of p53 and Bcl-2 [68,69].…”

Review and pooled analysis of studies on -607(C/A) and -137(G/C) polymorphisms in IL-18 and cancer risk

“…Using these terms, a total of 35 articles were retrieved, of which 17 [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] articles according to the inclusion criteria reported on studies examining the association between IL-18 -607(C/A) or -137(G/C) polymorphism and cancer risk.…”

“…The functional significance of these two SNPs has been shown that the C allele at position -607 and the G allele at position -137 were attributed to the IL-18 higher transcription and protein production [11,12]. These two SNPs have been investigated in several types of cancer such as renal cell carcinoma [13], ovarian cancer [14,28], breast cancer [15], nasopharyngeal carcinoma [16,20,22], cervical cancer [17,29], esophageal squamous cell carcinoma [18], prostate cancer [19], lung cancer [21], stomach cancer [23], colorectal cancer [23,25], head and neck squamous cell carcinoma [24], oral cancer [26] and lymphomas [27].…”